Table 1.

Summary of immune checkpoint-targeting antibodies.

Target	Antibody	Trade name	Isotype	Initial approval time
PD1	Pembrolizumab	Keytruda	IgG4	Sep 05, 2014
	Nivolumab	Opdivo	IgG4	Jun 22, 2015
PDL1	Atezolizumab	Tecentriq	IgG1	May 18, 2016
	Avelumab	Bavencio	IgG1	Mar 23, 2017
	Durvalumab	Imfinzi	IgG1	May 1, 2017
CTLA4	Ipilimumab	Yervoy	IgG1	Mar 25, 2011
	Tremelimumab	\	IgG2	Apr 15, 2015